Bladder Cancer

An expert discusses the future of immunotherapy in light of new frontline treatments like Keytruda that have been demonstrating positive results for patients with non–muscle invasive bladder cancer.

Women with frequent urinary tract infections (UTIs) were more likely to experience lower quality diagnostic processes when it comes to screening for bladder and kidney cancer.

Although muscle-invasive disease is often treated by removal of the bladder, experts reveal potential high risk of death.

At the 2019 Genitourinary Cancers Symposium, Arjun V. Balar discussed the past, present and future of immunotherapy for the treatment of bladder cancer.

After a review of more than 600,000 people, researchers discovered an association between foods consumed and bladder cancer risk.

Using tumor DNA found in urine, researchers believe they have found a method to diagnose and monitor bladder cancer that outperforms standard tests.

After patients with non–muscle invasive bladder cancer fail to respond to treatment with BCG immunotherapy, Keytruda (pembrolizumab) may induce responses in these high-risk patients.

Vofatamab (B-701) may be safe and effective for patients with locally advanced or metastatic bladder cancer with an FGFR3 mutation who have relapsed after, or are refractory to, at least one prior line of chemotherapy, according to preliminary findings.

An integrative model helped to determine which patients with bladder cancer may benefit from checkpoint inhibitor therapy.

Although chemotherapy and radical cystectomy are traditionally used to treat muscle-invasive disease, a recent analysis shows similar overall survival outcomes in patients treated with chemoradiotherapy.

Older adults may be at an increased risk for a heart attack or stroke five months before they are even diagnosed with cancer – a risk that peaked in the month prior to diagnosis, according to a report published in Blood.

A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.

While the treatment landscape continues to grow in bladder cancer, researchers should continue to follow the evidence, but accrual of patients in clinical trials is also key, according to Petros Grivas, M.D., Ph.D.

Patients with muscle-invasive bladder cancer who were treated with a dose-dense regimen of neoadjuvant chemotherapy followed by radical cystectomy (surgery to remove the urinary bladder) experienced more complete responses to treatment compared with the current standard of neoadjuvant chemotherapy.

The treatment paradigm for bladder cancer has been quite exciting in the last few years, and even more is yet to come, according to Petros Grivas, M.D., Ph.D.

Although immunotherapies show promise for patients, there are still challenges ahead.

Patients with platinum-pretreated metastatic urothelial carcinoma who were treated with a higher dosage of Yervoy (ipilimumab) in combination with Opdivo (nivolumab) experienced improved survival and tolerable side effects, according to findings from the phase 1/2 CheckMate-032 trial.

The immunotherapy agent Keytruda is showing promise for treating non-muscle invasive bladder cancer, according to a recent study.

In a recent survey, individuals in remission reported a more positive experience with bladder cancer compared with their counterparts who currently have active disease.

While universal screening for Lynch syndrome is currently only recommended for patients with colorectal and endometrial cancers, a new study recently published in The American Journal of Surgical Pathology suggests this for patients with upper tract urothelial carcinoma, too.

Can providers decrease opioid prescriptions after surgery, while still managing care adequately?

Immunotherapy has been a buzzworthy topic in the field of bladder cancer over the last couple of years. However, according to a Food and Drug Administration (FDA) safety warning, patients with metastatic disease may need to have their treatment altered.

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

Researchers determined that the use of methotrexate, vinblastine, doxorubicin and cisplatin before cystectomy may induce better outcomes for patients with advanced bladder cancer.

A new test that identifies which bladder cancer tumors will become invasive could help reduce health care costs and over-treatment in patients.

Stromal cells – known to provide structure to one’s organs – found in bladder cancer may explain why some patients do not respond to Opdivo (nivolumab) treatment.

Some patients eligible for bladder surgery due to cancer may safely opt to preserve the organ.

After chemotherapy, immunotherapy has become the standard treatment for bladder cancer. Will it ever play a bigger role?

While there is currently no definitive way to predict who will respond and who will not, researchers at Brighton and Sussex Medical School in the United Kingdom are working on a blood test that could identify about half of those who may not.

CURE spoke with Matthew Mossanen, M.D., from the Division of Urology at Brigham and Women’s Hospital, about what Bacillus Calmette-Guérin (BCG) is and what patients should know about this treatment option.